Development of a Buchwald–Hartwig Amination for an Accelerated Library Synthesis of Cereblon Binders
In recent years, targeted protein degradation (TPD) has emerged as a powerful therapeutic modality utilizing both heterobifunctional ligand-directed degraders (LDDs) and molecular glues (e.g., CELMoDs) to recruit E3 ligases for inducing polyubiquitination and subsequent proteasomal degradation of target proteins. The immunomodulatory drugs lenalidomide and pomalidomide bind to cereblon (CRBN), a substrate receptor of the CRL4A E3 ligase complex, to initiate degradation of neosubstrates critical for cell survival. Recently, nonlenalidomide or pomalidomide CRBN binders, known as alternate glutarimides, have gained popularity, offering potential degraders with varying physicochemical properties. Specifically, 3-substituted indazole derivatives have emerged as potent CRBN binders. We developed conditions for the direct cross-coupling of unprotected glutarimides with amines, streamlining the synthesis of alternative CRBN binders. This manuscript describes the rapid synthesis of 30 CRBN binders, their characterization as potential degraders and a cryo-EM structure of the CRBN/DDB1 with a representative compound (<b>6</b>).
Authors
- Tuan‐Anh Phan (ORCID: https://orcid.org/0000-0002-1657-8400)
- Hannah L. Powers
- Jennifer Buenviaje
- Natalie Holmberg‐Douglas (ORCID: https://orcid.org/0009-0007-5629-4756)
- J. Zhu (ORCID: https://orcid.org/0000-0001-5436-4262)
- Christoph W. Zapf (ORCID: https://orcid.org/0000-0001-5153-5206)
- Gody Khambatta
- Deborah S. Mortensen (ORCID: https://orcid.org/0000-0002-9144-0962)
- Jianqing Li (ORCID: https://orcid.org/0000-0002-8445-9796)
- Anastasia Lejava
- Giulianna A. Miseo
Institutions
- Bristol-Myers Squibb (United States) (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1021/acsmedchemlett.4c00462
- Citations
- 6
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- National Science Foundation
- Bristol-Myers Squibb
- Princeton Center for Complex Materials
- Materials Research Science and Engineering Center, Harvard University
- Division of Materials Research